Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma

Phase 1

Completed

Conditions: Lung Cancer
Malignant Mesothelioma

First Posted Date: 2004-08-20

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00003974

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-08-16

Last Posted Date: 2014-05-02

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00003340

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Lung Cancer
Carcinoma, Non-Small-Cell Lung

First Posted Date: 2004-08-12

Last Posted Date: 2007-12-24

Lead Sponsor: Cell Genesys

Target Recruit Count: 100

Registration Number: NCT00089726

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-08-11

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 25

Registration Number: NCT00002865

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

Phase 1

Completed

Conditions: Multiple Myeloma

First Posted Date: 2004-08-06

Last Posted Date: 2012-04-19

Lead Sponsor: University of Arkansas

Target Recruit Count: 10

Registration Number: NCT00089453

Locations: 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-08-05

Last Posted Date: 2013-04-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT00003957

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Phase 2

Withdrawn

Conditions: Lymphoma

First Posted Date: 2004-08-05

Last Posted Date: 2015-08-19

Lead Sponsor: Hoag Memorial Hospital Presbyterian

Registration Number: NCT00004039

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Splenic Marginal Zone Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Testicular Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage I Adult Diffuse Large Cell Lymphoma
Waldenström Macroglobulinemia

Interventions: Biological: rituximab
Drug: prednisone
Drug: cyclophosphamide
Drug: doxorubicin
Drug: vincristine
Radiation: indium In 111 ibritumomab tiuxetan
Radiation: radiation therapy
Procedure: positron emission tomography

First Posted Date: 2004-08-05

Last Posted Date: 2017-05-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT00088881

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-08-04

Last Posted Date: 2013-01-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 102

Registration Number: NCT00003784

Locations: 🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 84 locations

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Phase 2

Completed

Conditions: Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes
Thymic Carcinoma

First Posted Date: 2004-08-04

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 90

Registration Number: NCT00003662

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
University of Florida Health Science Center, Gainesville, Florida, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy